2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1212

Superiority of Musculoskeletal Ultrasound (MSUS) over Clinical Examination Regarding Detection of Arthritis in Patients with Systemic Sclerosis
Abstract Number: 616

Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX
Abstract Number: PP13

Support Groups and Patient Centred Care; Making a Difference in the Lives of People with Autoimmune and Rheumatic Conditions in Ghana
Abstract Number: 66

Suppression of Inflammatory Arthritis, in Human Paraoxonase 1 Transgenic Mice, Correlates with Upregulation of the Hepatic Glutathione Pathway and Reduction of Bioactive Lipid Mediators
Abstract Number: 1000

Surface Adenosine Monophosphate Deaminase 2 As a Novel Regulator Modifying Ectonucleotidase-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Abstract Number: 823

Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings
Abstract Number: 2609

Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Abstract Number: 1485

Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Abstract Number: 2820

Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Abstract Number: 2899

Sustained Drug-Free Remission in Early RA Following Methotrexate-Based Strategy: Role of the JAK-STAT Pathway
Abstract Number: 1659

Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
Abstract Number: 1869

Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
Abstract Number: PP02

Sustained Weight Loss Managed by Multiple Medical Specialists
Abstract Number: 179

Swimming Against the Stream- the Fishbowl Discussion Method As an Interactive Tool for Medical Conferences – Experiences from the 11. European Lupus Meeting
Abstract Number: 2533

Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].